Collegium Pharmaceutical Files 8-K
Ticker: COLL · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1267565
| Field | Detail |
|---|---|
| Company | Collegium Pharmaceutical, Inc (COLL) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC filing, financial-reporting
TL;DR
Collegium Pharma filed a routine 8-K with SEC, mostly exhibits. Nothing major to see here.
AI Summary
On June 13, 2024, Collegium Pharmaceutical, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures rather than a specific material event. No significant financial figures or new strategic initiatives were detailed in the provided excerpt.
Why It Matters
This filing indicates Collegium Pharmaceutical is making standard disclosures to the SEC, which is important for investors to stay informed about the company's regulatory compliance and financial reporting.
Risk Assessment
Risk Level: low — The filing appears to be a standard disclosure of financial statements and exhibits, not indicating any immediate or significant risks.
Key Players & Entities
- COLLEGIUM PHARMACEUTICAL, INC. (company) — Registrant
- June 13, 2024 (date) — Date of Report
- 001-37372 (company) — Commission File Number
- 100 Technology Center Drive Suite 300 Stoughton , MA 02072 (company) — Address of principal executive offices
- 781-713-3699 (company) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Collegium Pharmaceutical, Inc.?
The primary purpose of this 8-K filing is to report Other Events and to provide Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on June 13, 2024.
What is Collegium Pharmaceutical, Inc.'s state of incorporation?
Collegium Pharmaceutical, Inc. is incorporated in Virginia.
What is the principal executive office address for Collegium Pharmaceutical, Inc.?
The principal executive office address is 100 Technology Center Drive Suite 300 Stoughton, MA 02072.
What is the Commission File Number for Collegium Pharmaceutical, Inc.?
The Commission File Number for Collegium Pharmaceutical, Inc. is 001-37372.
Filing Stats: 461 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-06-13 08:05:25
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share COLL The NASDAQ Global Sele
Filing Documents
- tm2417144d1_8k.htm (8-K) — 22KB
- tm2417144d1_ex99-1.htm (EX-99.1) — 64KB
- tm2417144d1_ex99-1img001.jpg (GRAPHIC) — 19KB
- 0001104659-24-071070.txt ( ) — 293KB
- coll-20240613.xsd (EX-101.SCH) — 3KB
- coll-20240613_lab.xml (EX-101.LAB) — 33KB
- coll-20240613_pre.xml (EX-101.PRE) — 22KB
- tm2417144d1_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Information. On June 13, 2024, Collegium Pharmaceutical, Inc. issued a press release announcing the U.S. Food and Drug Administration ("FDA") has granted pediatric exclusivity for Nucynta and Nucynta ER ("the Nucynta Franchise"), extending exclusivity of the Nucynta Franchise an additional six months, to January 3, 2027, for Nucynta and December 27, 2025, for Nucynta ER. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. 99.1 Press Release, dated June 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 13, 2024 Collegium Pharmaceutical, Inc. By: /s/ Colleen Tupper Name: Colleen Tupper Title: Executive Vice President and Chief Financial Officer